~~<i id='EE178E1D11'><strike id='EE178E1D11'><tt id='EE178E1D11'><pre id='EE178E1D11'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

comprehensive

author：focus 2025-09-30 17:27:15 - browse：63

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Medical device lobby: We're tired of waiting on Medicare coverage

entertainment

Wikipedia

focus

Wikipedia

focus

AdobeMedicaltechnologylobbyAdvaMedisfedupwiththeCentersforMedicareandMedicaidServices.Inalettersentt

WSS

Why getting cancer drugs just got harder for rural patients

EU moves toward latest gene techniques in food production to counter climate change, shortages

FogPharma raises $145 million in rare Series E round

Medical device lobby: We're tired of waiting on Medicare coverage

Scientists unlock the key to scar

City of Memphis, police chief oppose effort to delay lawsuit in Tyre Nichols case

hotspot

comprehensive

entertainment

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Obesity now affects over 1 billion people worldwide, study finds

As demand for Covid shots wanes, Moderna seeks its next success

Flu vaccine offering decent levels of protection this winter, new data show

The high cost of giving birth even with insurance

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

How one medical school became remarkably diverse

Search warrant issued in 1996 disappearance of Kristin Smart

State Dept. review finds Biden bears some blame for Afghanistan failures

In search for therapies for solid tumors, companies turn to claudin

Wikipedia

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

Pentagon will tighten controls on classified information after Discord leak

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Pope Francis asks Church to identify 21st

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

focus

Wikipedia

Wikipedia

focus